MINIREVIEW

Metabolism and Hepatotoxicity of Pyrazinamide, an Antituberculosis Drug. Zahir Hussain, Junjie Zhu, and Xiaochao Ma .......................................................... 679

ARTICLES

Investigation into MAO B–Mediated Formation of CC112373, a Major Circulating Metabolite of Ozanimod, in Humans and Preclinical Species: Stereoselective Oxidative Deamination of (S)-Enantiomer of Indaneamine (RP101075) by MAO B. April Bai, Veerabahu Shammugasundaram, Julie V. Selkirk, Sekhar Surapaneni, and Deepak Dalvie . . . . . . . . . . . . . . . 601

Proteomic Quantification of Changes in Abundance of Drug-Metabolizing Enzymes and Drug Transporters in Human Liver Cirrhosis: Different Methods, Similar Outcomes. Eman El-Khateeb, Zubida M. Al-Majdoub, Amin Rostami-Hodjegan, Jill Barber, and Brahim Achour ............................. 610

Pharmacokinetics, Disposition, and Biotransformation of [14C]Omecamtiv Mecarbil in Healthy Male Subjects after a Single Intravenous or Oral Dose. Ashit Trivedi, Jan Wahlstrom, Mia Mackowski, Sandeep Dutta, and Edward Lee . . . . . . . . . . . . . . . . . 619

BCRP/ABCG2 Transporter Regulates Accumulation of Cadmium in Kidney Cells: Role of the Q141K Variant in Modulating Nephrotoxicity. Xia Wen, Danielle Kozlosky, Ranran Zhang, Cathleen Doherty, Brian Buckley, Emily Barrett, and Lauren M. Aleksunes ........................................... 629

Characterization of a Novel CYP1A2 Knockout Rat Model Constructed by CRISPR/Cas9. Dongyi Sun, Jian Lu, Yuanjin Zhang, Jie Liu, Zongjun Liu, Bingyi Yao, Yuanqing Guo, and Xin Wang . . . . . . . . . . . . . . . . . . . . . . . 638

Supplemental material is available online at http://dmd.aspetjournals.org.

About the cover: Docking of ozanimod metabolite RP101075 and its enantiomer (RP101074) in MAO B active site. See the article by Bai et al. (dx.doi.org/10.1124/dmd.121.000447).